Ascendis Pharma (ASND) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
2 figures withheld by our checks. Each blank figure names its reason.
56.9mn → 62.0mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
▲574% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.
$20.4M returned vs $53.3M of FCF in FY25. Buybacks covered by cash flow.
-32¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Over this window: gross 54.7% → 86.8%. Net margin -31.7% is below the sector median.
| Line item | FY25 † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 845,146.9 | 845,146.9 | 376,404.8 | 295,043.5 | 54,745.9 | 8,803.1 | ▲124.5% | +213.0% |
Cost of revenue | 111,392.2 | 111,392.2 | 45,811.5 | 49,109.7 | 12,984.2 | 3,987.3 | ▲143.2% | +129.9% |
Gross profit | 733,754.7 | 733,754.7 | 330,593.3 | 245,933.7 | 41,761.8 | 4,815.8 | ▲122.0% | +251.3% |
Research & development | 356,329.6 | 356,329.6 | 317,779.8 | 457,362.8 | 406,121.8 | 334,862.3 | ▲12.1% | +1.6% |
Selling, general & admin | 537,352.7 | 537,352.7 | 301,361.1 | 292,490.3 | 236,668.6 | 181,291.7 | ▲78.3% | +31.2% |
Total operating expenses | 893,682.3 | 893,682.3 | 619,140.9 | 749,853.2 | 642,790.4 | 516,154.0 | ▲44.3% | +14.7% |
Operating incomefeeds ROC rank | −159,927.6 | −159,927.6 | −288,547.6 | −503,919.5 | −601,028.6 | −511,338.2 | ▲44.6% | — |
Other income, net | −89,639.6 | −89,639.6 | −97,794.2 | −20,578.6 | −17,120.0 | 76,790.4 | — | — |
Pretax income | −249,567.2 | −249,567.2 | −386,341.8 | −524,498.1 | −618,148.6 | −434,547.8 | ▲35.4% | — |
Income tax | 18,053.5 | 18,053.5 | 5,013.0 | 8,078.6 | 5,752.3 | −415.4 | ▲260.1% | +46.4% (22→25) |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −267,620.7 | −267,620.7 | −391,354.7 | −532,576.7 | −623,900.9 | −434,132.4 | ▲31.6% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −4.41 | −4.41 | −6.76 | −9.46 | −11.13 | −7.00 | ▲34.7% | — |
Diluted shares (mn) | 61.98 | 61.98 | 60.69 | 57.71 | 57.15 | 56.94 | ▲2.1% | +2.1% |
| Margins | ||||||||
Gross margin81st pct in Healthcare | 86.8% | 86.8% | 87.8% | 83.4% | 76.3% | 54.7% | ▼1.0pp | +32.1pp |
Operating margin | −18.9% | −18.9% | −76.7% | −170.8% | −1097.9% | −5808.6% | ▲57.7pp | +5789.7pp |
Net margin19th pct in Healthcare | −31.7% | −31.7% | −104.0% | −180.5% | −1139.6% | −4931.6% | ▲72.3pp | +4899.9pp |
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Ascendis Pharma's revenue last fiscal year?
Ascendis Pharma reported revenue of $845.1M in fiscal 2025, up 124.5% from fiscal 2024.
What was Ascendis Pharma's net income?
Ascendis Pharma reported net income of −$267.6M in fiscal 2025, a net margin of −31.7%.

